Red Dichromatic Imaging for Improving Post-Biopsy Bronchoscopic Field Visibility

The goal of this observational study is to learn whether red dichromatic imaging (RDI) can help doctors see the bronchoscopic field more clearly after a biopsy. The study will include adults who need a bronchoscopic biopsy because doctors can see an abnormal area inside the airway.During a bronchoscopic biopsy, bleeding can happen after tissue is taken. Blood may cover the biopsy area and make it harder for doctors to see where to continue the procedure.

RDI is an imaging mode that uses special colors of light to help show blood-covered areas more clearly.The main question this study aims to answer is:Does RDI improve visibility of the bronchoscopic field after bleeding caused by bronchoscopic biopsy? Researchers will compare images taken with standard white light imaging and RDI during the same bronchoscopy procedure. Both types of images will be taken after the first biopsy and before any field-clearing treatment is done.

Participants will have bronchoscopic biopsy as part of their regular medical care, have images taken using standard white light imaging and RDI during the same procedure, have routine follow-up for possible medical problems after bronchoscopy. Taking part in this study will not add extra biopsies or change the participant's regular medical care.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Bronchoscopic Biopsy Airway Lesion Biopsy-related Bleeding Hemorrhage Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Anhui Chest Hospital, Hefei, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥18 years.
Visible abnormal endobronchial lesion under bronchoscopy, including endobronchial neoplasm, mucosal abnormality, airway stenosis, or other lesion requiring biopsy to determine its nature.
Provision of informed consent to participate in this clinical study and signing of the informed consent form.

Exclusion criteria

Presence of contraindications to bronchoscopy, such as severe cardiopulmonary disease, coagulation dysfunction (including patients receiving anticoagulant therapy and/or anticoagulant drugs who have not discontinued these drugs for more than 5 days before the examination), poor tolerance of anesthesia, psychiatric disease, or severe neurosis.
Intra-procedural decrease in SpO₂ or inability to tolerate bronchoscopy.
Obvious airway bleeding observed during bronchoscopy that may increase the risk of worsening the patient's condition.
Images that are obviously blurred or out of focus, or that contain severe reflection, bubbles, or instrument obstruction, making subsequent image analysis impossible.
Inability to cooperate with the study for any reason, or any other condition that the investigator considers unsuitable for study participation.

Treatment and study plan

Red Dichromatic Imaging (RDI)

Device

Red dichromatic imaging (RDI) is an optical imaging mode used during bronchoscopy. In this observational study, RDI images and standard white light imaging images will be collected during the same clinically indicated bronchoscopy procedure after the biopsy. RDI will be evaluated for its ability to improve post-biopsy bronchoscopic field visibility. The study will not assign participants to treatment groups, add extra biopsies, or change routine clinical care.

Primary outcomes

Proportion of post-biopsy bronchoscopic fields judged suitable for direct procedural continuation

Time frame: Periprocedural

Paired white light imaging and red dichromatic imaging images will be assessed by independent evaluators. A bronchoscopic field will be judged suitable for direct procedural continuation if the biopsy site, lesion surface, or lesion boundary remains identifiable and biopsy or subsequent bronchoscopic procedures can continue without additional field-clearing intervention.

Secondary outcomes

Visual distinguishability score between the bleeding area and surrounding blood-covered background

Time frame: Periprocedural

Paired white light imaging and red dichromatic imaging images will be assessed by independent evaluators. The visual distinguishability between the biopsy-related bleeding area and the surrounding blood-covered background will be scored on a 4-point scale. A score of 1 indicates that the two areas are almost indistinguishable, and a score of 4 indicates that the two areas are clearly distinguishable and easy to identify.
Objective color difference between the bleeding area and surrounding blood-covered background

Time frame: Periprocedural

Objective color difference will be measured using paired white light imaging and red dichromatic imaging images. Regions of interest will be selected from the biopsy-related bleeding area and the surrounding blood-covered background. Color parameters will be measured in the CIE 1976 L*a*b* color space, and the overall color difference will be calculated as ΔE. Differences in the L*, a*, and b* channels may also be analyzed.

Other outcomes

Proportion of bronchoscopic fields judged suitable for procedural continuation after one field-clearing intervention

Time frame: Periprocedural

Among cases in which both white light imaging and red dichromatic imaging are initially judged unsuitable for direct procedural continuation, one field-clearing intervention may be performed according to clinical need. This may include suction, irrigation, cold saline, topical epinephrine, or other necessary measures. After this intervention, paired white light imaging and red dichromatic imaging images will be assessed to determine whether the bronchoscopic field is suitable for continuation of biopsy or subsequent bronchoscopic procedures.

Study contacts

Contact information is provided by the study sponsor or research team.

Zhongbo Chen

CONTACT

[email protected]

86+13777125910

Sponsors and collaborators

Lead sponsor

First Affiliated Hospital of Ningbo University

Network

Collaborators

Anhui Chest Hospital
Huzhou Central Hospital
Lanxi Hospital of Traditional Chinese Medicine
Shanghai Chest Hospital
The Second Affiliated Hospital of Jiaxing University
Zhoushan Hospital of Zhejiang

Registry information

Important dates

Study start: 2026
Primary completion: 2026
Study completion: 2026
First posted: Jun 17, 2026
Registry last updated: Jun 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting